Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 2 (1)

Trial Status

Unknown1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07237100Phase 2RecruitingPrimary

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

NCT00584493UnknownPrimary

Treatment Use Study for Advanced Melanoma.

Showing all 2 trials

Research Network

Activity Timeline